Cannabinoid

Among patients seen at an orthopedic clinic, 81.3% were open to receiving THC-based products and 90.1% were open to receiving CBD-based products for the management of musculoskeletal pain, according to published results.

Despite a lack of “gold standard” evidence surrounding cannabis use for musculoskeletal pain, rheumatologists must not turn a blind eye to how such products are used by their patients in the real world, according to researchers.

BOSTON — There is some evidence that cannabinoids may help with neuropathic pain, chemotherapy-induced nausea/vomiting and MS-associated spasticity, “but it’s not exactly a slam dunk,” a speaker said.

A law allowing for medical cannabis research could have far-reaching implications in rheumatology and across the health care spectrum, but there are still significant hurdles to clear before cannabinoids become part of routine care.

Skye Bioscience has completed enrollment for its phase 2a trial of SBI-100, a cannabinoid receptor type 1 agonist being developed for patients with primary open-angle glaucoma or ocular hypertension, according to a company press release.

Over the past few years, products based on CBD and medical marijuana have become widely available and accepted as treatments for various ailments.

DESTIN, Fla. — Managing expectations about efficacy is critical for patients with rheumatic diseases using cannabinoid products for pain, sleep or other complications, according to a presenter at the 2023 Congress of Clinical Rheumatology-East.

DESTIN, Fla. — Significantly more research into the risks and benefits of cannabinoids is necessary to keep pace with both medicinal and recreational use in the U.S., noted a presenter at the 2023 Congress of Clinical Rheumatology-East.

Biopharmaceutical company Zelira Therapeutics has received $8.6 million in funding for the study of its cannabinoid drug for use in patients with autism spectrum disorder, according to a company press release.

In double-blind, placebo-controlled cannabinoid trials, placebo was significantly associated with pain reduction. Still, the trials received positive media attention, which researchers said could shape the results of future cannabinoid trials.